| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514400900 | Appetite or satiation affecting | 73 |
| 20100279930 | HUMAN PANCREATIC POLYPEPTIDE (HPP) ANALOGUES AND THEIR EFFECTS ON FEEDING BEHAVIOUR - Analogue of human Pancreatic Polypeptide which differs from native human pancreatic polypeptide in respect of amino acid substitutions at one or more residues; and also uses of one or more of said compounds, methods that use one of more of said compounds, compositions comprising one or more of said compounds; and methods of making said compounds. | 11-04-2010 |
| 20100323955 | METHODS FOR TREATING OBESITY AND OBESITY RELATED DISEASES AND DISORDERS - Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain. | 12-23-2010 |
| 20100331245 | PEPTIDE YY ANALOGS - The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion. | 12-30-2010 |
| 20110021420 | MODIFICATION OF FEEDING BEHAVIOUR - The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and/or increase energy expenditure. | 01-27-2011 |
| 20110028391 | Use of GLP-1 Peptides - GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety. | 02-03-2011 |
| 20110039767 | FOOD COMPOSITIONS - The present inventors have found that collagen hydrolysate can be favorably used for the preparation of an edible composition for limiting voluntary food intake and hence are suitable for prevention and treatment of overweight and obesity. | 02-17-2011 |
| 20110039768 | FISH PROTEIN HYDROLYSATE HAVING A SATIETOGENIC ACTIVITY, NUTRACEUTICAL AND PHARMACOLOGICAL COMPOSITIONS COMPRISING SUCH A HYDROLYSATE AND METHOD FOR OBTAINING SAME, - The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically, the protein hydrolysate according to the invention enables stimulation of the secretion of endogenous cholescystokinins (CCKs) and of endogenous glucagon-like peptide 1 (GLP1) molecules by intestinal cells and the supply of exogenous CCKs. The fish protein hydrolysate according to the invention is obtained by enzymatic hydrolysis of at least one protein source selected from the group composed of the pelagic fish species | 02-17-2011 |
| 20110046047 | Bone Morphogenetic Proteins for Appetite Control - Methods of decreasing appetite for food intake by administering bone morphogenetic proteins (BMPs), e.g., BMP7, or agonists/peptidomimetics thereof. | 02-24-2011 |
| 20110065633 | ESTER-BASED PEPTIDE PRODRUGS - Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 03-17-2011 |
| 20110071075 | PROMOTER FOR BICARBONATE SECRETION IN GASTROINTESTINAL TRACT - A substance is described which can prevent or treat a disease associated with the secretion of an acid. A calcium receptor activator is the active ingredient in a composition which promotes bicarbonate secretion in a gastrointestinal tract. Examples of the calcium receptor activator include γ-Glu-X-Gly, wherein X represents an amino acid or an amino acid derivative, γ-Glu-Val-Y, wherein Y represents an amino acid or an amino acid derivative, γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, γ-Glu-Met(O), γ-Glu-γ-Glu-Val, γ-Glu-Val-NH2, γ-Glu-Val-ol, γ-Glu-Ser, γ-Glu-Tau, γ-Glu-Cys(S-Me)(O), γ-Glu-Leu, γ-Glu-Ile, γ-Glu-t-Leu, and γ-Glu-Cys(S-Me). | 03-24-2011 |
| 20110092416 | Vitamine B12 - Peptide Conjugates for Oral Delivery - Compositions containing a therapeutic peptide covalently linked to Vitamin B | 04-21-2011 |
| 20110098217 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY - Glucagon analogs are disclosed that exhibit both glucagon antagonist and GLP-1 agonist activity. In one embodiment, the glucagon antagonist/GLP-1 agonist comprises a modified amino acid sequence of native glucagon, in which the first one to five N-terminal amino acids of native glucagon is deleted and in which the alpha helix is stabilized. | 04-28-2011 |
| 20110098218 | MODULATORS OF STAT3 SIGNALLING - The invention relates to methods for identifying compounds which modulate the interaction between STAT3 an SP1. A peptide is provided which is able to bind STAT3 and interfere with the interaction of STAT3 and SP1. The invention provides methods for identifying compounds which are capable of binding to the peptide and thus release interference with the interaction between STAT3 and SP1, as well as methods for identifying inhibitors and enhancers of the STAT3 SP1 interaction. Compounds identified by the methods of the invention are useful in the repression or stimulation of appetite in a patient, useful for the treatment of leptin resistance, obesity and anorexia. | 04-28-2011 |
| 20110152181 | OXYNTOMODULIN PEPTIDE ANALOGUE - The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity. | 06-23-2011 |
| 20110218141 | Leptin therapy to increase muscle mass and to treat muscle wasting conditions - The present invention provides a method of treating a subject suffering from a muscle wasting disorder comprising the step of administering to the subject an effective dose of leptin, leptin analog or leptin derivative. | 09-08-2011 |
| 20110230399 | Methods for Treating Obesity Related Disease - The present invention relates to methods and products for the treatment of obesity. The invention discloses a method of treating obesity related disease in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a composition which causes the continued down regulation of the NPY-1 or NPY-5 receptor. | 09-22-2011 |
| 20110245159 | Salts, Solvates and Pharmaceutical Compositions of Macrocyclic Ghrelin Receptor Agonists and Methods of Using the Same - The present invention provides novel salts and solvates of macrocyclic compounds that bind to and/or are functional agonists of the ghrelin (growth hormone secretagogue) receptor. The invention also relates to polymorphs of these salts and solvates, pharmaceutical compositions containing these salts or solvates, and methods of using the pharmaceutical compositions. These pharmaceutical compositions are useful as therapeutics for a range of disease indications, in particular, for treatment and prevention of gastrointestinal disorders including, but not limited to, postoperative ileus, gastroparesis, including diabetic and postsurgical gastroparesis, opioid bowel dysfunction, chronic intestinal pseudo-obstruction, short bowel syndrome, functional gastrointestinal disorders and gastrointestinal dysmotility, such as that occurring in conjunction with other disease states, in critical care situations or as a result of treatment with pharmaceutical agents. Additionally, the pharmaceutical compositions have application to the treatment and prevention of metabolic and/or endocrine disorders, cardiovascular disorders, central nervous system disorders, bone disorders, inflammatory disorders, hyperproliferative disorders, disorders characterized by apoptosis and genetic disorders. | 10-06-2011 |
| 20110245160 | UNACYLATED GHRELIN FRAGMENTS AS THERAPEUTIC AGENT IN THE TREATMENT OF OBESITY - A method for treating obesity and more particularly a method for treating diet-induced obesity in a subject comprising administering to said subject an isolated unacylated ghrelin peptide as set forth in SEQ ID NO: 1, a fragment thereof or a cyclic fragment thereof such as a cyclic unacylated ghrelin fragment. The method being achievable without affecting the food intake of the subject. | 10-06-2011 |
| 20110257087 | Protein Hydrolysate Compositions Having Enhanced CCK Releasing Activity - The present invention provides protein hydrolysate compositions having enhanced cholecystokinin (CCK) releasing activity that can be used to promote satiety. | 10-20-2011 |
| 20110263491 | COMPOSITIONS AND METHODS FOR THE CONTROL, PREVENTION AND TREATMENT OF OBESITY AND EATING DISORDERS - Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition. | 10-27-2011 |
| 20110306542 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS - Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for use in structural analyses of the GLP-1 receptor. Methods of synthesis, methods of therapeutic and/or prophylactic use, and methods of use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor of such compounds are provided. | 12-15-2011 |
| 20120015876 | CONJUGATES OF GLP-1 AGONISTS AND USES THEREOF - The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes. | 01-19-2012 |
| 20120035100 | SATIATION PEPTIDE ADMINISTRATION - Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY. | 02-09-2012 |
| 20120040893 | MODIFICATION OF FEEDING BEHAVIOUR - Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, simultaneously or sequentially, thereby decreasing the calorie intake of the subject. | 02-16-2012 |
| 20120094898 | PEPTIDE DERIVATIVE - The present invention relates to a peptide derivative selected from the group consisting of
| 04-19-2012 |
| 20120108504 | LEPTIN AGONIST AND METHODS OF USE - Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, type II diabetes, appetite control after bariatric surgery, insulin resistance, lipodystrophy and hypothalamic amenorrhea, obesity-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance. | 05-03-2012 |
| 20120115776 | ADIPONECTIN-CONTAINING EATING BEHAVIOR CONTROL AGENT FOR ORAL ADMINISTRATION - Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises a transformant capable of expressing adiponectin. Also specifically disclosed is a food composition for controlling appetite, which comprises the appetite control agent. | 05-10-2012 |
| 20120122773 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE - The present invention provides a compound of formula (I): | 05-17-2012 |
| 20120142586 | TREATMENT FOR OBESITY - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 06-07-2012 |
| 20120149635 | TREATMENT FOR OBESITY - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 06-14-2012 |
| 20120172294 | TREATMENT OF DISEASES - The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal, (iii) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing a blood lipid level in an animal in need thereof, (vi) a method of treating non-alcoholic steatohepatitis in an animal, and (vii) a method of inhibiting adipogenesis. The methods comprise administering an effective amount of an active ingredient, wherein the active ingredient comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal. The invention also provides a kit comprising a container holding a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them; and instructions for administration. The diketopiperazines have the formula given in the application. | 07-05-2012 |
| 20130012432 | Peptides for Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 01-10-2013 |
| 20130023464 | NOVEL COMPOUNDS AND THEIR EFFECTS ON FEEDING BEHAVIOUR - Peptide analogues of PYY, compositions comprising said analogues and methods of using said analogues for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as diabetes and obesity, and for a reduction in appetite, reduction in food intake or reduction of calorie intake in a subject. | 01-24-2013 |
| 20130023465 | Use of Human Chorionic Gonadotropin (hCG) by Oral-Sublingual or Injectable Route as an Appetite-Suppressant Agent. - Use of Human Chorionic Gonadotropin (hCG) by oral-sublingual or injectable route for the treatment of several food disorders, as an appetite-suppressant agent, food compulsiveness as well as all of those pathologies related to hunger and/or appetite modifications, including overweight, obesity, anorexia, bulimia, emotional hyperphagia, without excluding other pathologies associated to overingestion or reduced ingestion. It also includes its use for the treatment of behavior disorders associated with an increased ingestion, either behavior disorders, neurosis, borderline personality disorders or psychosis, without excluding other psychosomatic disorders. | 01-24-2013 |
| 20130045915 | METHOD FOR WEIGHT LOSS AND KETOGENIC COMPOSITIONS - The present disclosure relates to a weight-loss composition including protein and fat and methods of use. The weight loss composition is substantially free of carbohydrates. The composition induces body weight loss when administered to a subject as the only source of nutrition for at least 12 hours. | 02-21-2013 |
| 20130225485 | Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders - Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition. | 08-29-2013 |
| 20130225486 | CYSTEINE AND FOOD INTAKE - The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the treatment and/or prevention of malnutrition and disorders related thereto. Such a composition may in particular, but not exclusively, be useful for the elderly population. | 08-29-2013 |
| 20130231278 | Peptides containing tryptophan - The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45. | 09-05-2013 |
| 20130261051 | Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals - The present invention relates to methods for treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of an insulin, insulin analogue or derivative thereof, which exhibits a prolonged profile of action, wherein said dosages are administered at intervals of varying length. | 10-03-2013 |
| 20130296231 | CHARGED NUTRITIVE PROTEINS AND METHODS - Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things. | 11-07-2013 |
| 20130296232 | PEPTIDES CONTAINING TRYPTOPHAN - The present invention relates to a composition comprising a tryptophan-containing peptide and having a Trp/LNAA ratio of more than 0.1 for decreasing eating or appetite during or after stress. | 11-07-2013 |
| 20130324461 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY - The invention includes methods of treating, preventing, or limiting obesity or weight gain, or reducing or suppressing appetite, by the administration of A2A adenosine receptor pathway agonists. The A2AR pathway agonists may be administered in conjunction with a therapeutic agent having a side effect of weight gain, in order to prevent or limit that weight gain. In some instances, the A2AR pathway agonist is administered as a sleeping pill, and in other instances the A2AR pathway agonist is administered in a non-drowsy formulation. | 12-05-2013 |
| 20130324462 | Method of Reducing The Effects of Chemotherapy Using Flagellin Related Polypeptides - The use of flagellin and flagellin related polypeptides for reducing cancer treatment side effects in mammals is described. | 12-05-2013 |
| 20130331315 | Protein Hydrolysate Compositions Having Enhanced CCK and GLP-1 Releasing Activity - The present invention provides protein hydrolysate compositions having enhanced cholecystokinin (CCK) and/or giuoagon-like peptide-1 (GLP-1) releasing activity and food forms incorporating the protein hydrolysate compositions, which can be used to promote satiety. | 12-12-2013 |
| 20130345123 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF - The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH | 12-26-2013 |
| 20140005105 | PLASMA ANTI-DIABETIC NUCB2 PEPTIDE (PLADIN) AND USES THEREOF | 01-02-2014 |
| 20140057838 | OSTEOBLAST-EXPRESSED LIPOCALIN 2 REGULATES GLUCOSE METABOLISM - Diseases including diabetes, metabolic syndrome, and obesity or obesity-related diseases are due to impairment in glucose metabolism. The skeleton has been shown to regulate energy metabolism and play a role in glucose metabolism. The present invention relates to methods for treating or preventing diseases such as diabetes, metabolic syndrome, and obesity or obesity-related by administering a therapeutically effective amount of osteoblast-expressed Lcn-2 or a biologically active fragment. | 02-27-2014 |
| 20140162943 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS - The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce β-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce GLP-1 receptor agonist compounds having improved GLP-1 receptor binding activity, enzymatic stability, or in vivo glucose lowering activity; and to develop GLP-1 receptor agonist compounds which have fewer amino acid residues. The disclosure also provides GLP-1 receptor agonist compounds, such as exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs, comprising the N-terminus conformationally constrained compounds. The compounds are useful for treating various diseases, such as diabetes and obesity. The disclosure also provides methods for chemically synthesizing the N-terminus conformationally constrained compounds. | 06-12-2014 |
| 20140213513 | Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists - The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 07-31-2014 |
| 20140221280 | NOVEL COMPOUNDS AND THEIR EFFECTS ON FEEDING BEHAVIOUR - Peptide containing sequence from both the GLP-1 peptide and glucagon peptide, compositions comprising said peptides and methods of using said peptides for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as obesity or diabetes, are provided | 08-07-2014 |
| 20140221281 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS - The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 08-07-2014 |
| 20140274887 | Compounds for Control of Appetite - This invention relates generally to neuropeptide Y (“NPY”) Y | 09-18-2014 |
| 20140342978 | Charged Nutritive Proteins and Methods - Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things. | 11-20-2014 |
| 20140349922 | LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS - Pegylated and reverse pegylated GLP-1/Glucaron receptor agonists including pharmaceutical compositions comprising the same and methods of using the same are disclosed. | 11-27-2014 |
| 20150011467 | OXYNTOMODULIN ANALOGUES AND THEIR EFFECTS ON FEEDING BEHAVIOUR - Compounds of the invention are novel peptide analogues of oxyntomodulin (oxm) in which one or more amino acids of the oxm sequence have been changed. Changing amino acids 15-24 of oxm to either amino acids 968-977 of the α-latrotoxin peptide (and variations thereof) or amino acids 15-24 of exendin-4 (and variations thereof), or combinations of sequences from these sources, and/or changing amino acids 27-33 of oxm to amino acids 27-33 of exendin-4, and/or the addition of amino acids to the C-terminus of the peptide, results in a series of analogues of oxm that demonstrate the oxm like activity of reducing food intake, and with certain embodiments a greater ability to decrease food intake. | 01-08-2015 |
| 20150011468 | USES OF CASEIN COMPOSITIONS - Casein compositions for increasing the rate of gastric emptying following ingestion of the composition, increasing the digestibility of a protein composition, or increasing the rate of delivery of amino acids to the blood, or for increasing the blood serum concentration of free leucine in a subject, preferably to substantially the same level as whey protein, the casein being about 10 to about 100% calcium depleted, having a degree of hydrolysis less than about 1% and having an unmodified phosphorylation pattern. | 01-08-2015 |
| 20150025001 | FISH PROTEIN HYDROLYSATE HAVING A SATIETOGENIC ACTIVITY, NUTRACEUTICAL AND PHARMACOLOGICAL COMPOSITIONS COMPRISING SUCH A HYDROLYSATE AND METHOD FOR OBTAINING SAME - The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically, the protein hydrolysate according to the invention enables stimulation of the secretion of endogenous cholescystokinins (CCKs) and of endogenous glucagon-like peptide 1 (GLP1) molecules by intestinal cells and the supply of exogenous CCKs. The fish protein hydrolysate according to the invention is obtained by enzymatic hydrolysis of at least one protein source selected from the group composed of the pelagic fish species | 01-22-2015 |
| 20150045292 | METHODS AND COMPOSITION FOR INDUCING SATIETY - A flowable or spoonable medicament, food, food ingredient or food supplement is useful for inducing satiety. It comprises a protein and a methylcellulose (MC), wherein the weight ratio w(protein)/w(MC) is at least 0.7/1.0 and the methylcellulose has anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is 0.36 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups. | 02-12-2015 |
| 20150051140 | MODIFICATION OF FEEDING BEHAVIOR - Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, simultaneously or sequentially, thereby decreasing the calorie intake of the subject. | 02-19-2015 |
| 20150065420 | VITAMIN D-GHRELIN CONJUGATES - The invention provides carriers that enhance the absorption, half-life or bioavailability of Ghrelin peptides. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties. | 03-05-2015 |
| 20150072924 | LONG-ACTING OXYNTOMODULIN VARIANTS AND METHODS OF PRODUCING SAME - This invention is directed to a chorionic gonadotrophin carboxy terminal peptide (CTP) modified dual GLP-1/Glucagon receptor agonist, and methods of producing and using the same. In one embodiment, the present invention provides a CTP-modified polypeptide comprising a dual GLP-1/Glucagon receptor agonist and at least one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus or carboxy terminus of said agonist. | 03-12-2015 |
| 20150072925 | Methods For Weight Loss And Ketogenic Compositions - The present disclosure relates to a weight-loss composition including protein and fat and methods of use. The weight loss composition is substantially free of carbohydrates. The composition induces body weight loss when administered to a subject as the only source of nutrition for at least 12 hours. | 03-12-2015 |
| 20150119320 | PEGYLATED OXM VARIANTS - A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed. | 04-30-2015 |
| 20160015784 | MIC-1 FUSION PROTEINS AND USES THEREOF - The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analogue thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds. | 01-21-2016 |
| 20160038487 | NOVEL GLP-1 RECEPTOR MODULATORS - Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ | 02-11-2016 |
| 20160038565 | Methods of Mitigating Side Effects of Radiation Exposure and Chemotherapy - Compositions and methods for treating toxicity associated with exposure to radiation and side effects of treatments for hyperproliferative disorders are provided. Typically the compositions are administered in an effective amount reduce one or more adverse side effects. The side effects to be treated include, but are not limited to reduced appetite and weight loss. The methods typically include administering to a subject a composition including a protein transduction domain, a target signal, and a transcription factor A—mitochondrial polypeptide in an amount effective to inhibit, reduce or alleviate weight loss or to increase or induce appetite. | 02-11-2016 |
| 20160082070 | METHODS OF TREATMENT USING WATER-SOLUBLE TRYPTOPHAN-CONTAINING PEPTIDES OBTAINED BY THE HYDROLYSIS OF HENS EGGS LYSOZYME - The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45. | 03-24-2016 |
| 20160082088 | COLLAGEN POWDER - Methods are disclosed for preparing a collagen powder, for example which may be used for the preparation of a satiety inducing food product. The collagen powder is suitable as a food additive in food products for the reduction of hunger and as a possible treatment of obesity and its pathophysiological consequenceos, such as metabolic syndrome. | 03-24-2016 |
| 20160089392 | Whey Protein and Resistant Starch Compositions to Reduce Body Mass Index - A nutritional composition comprised of whey protein (WP) and resistant starch (RS) designed to reduce body fat, body fat distribution and as a result lower Body Mass Index (BMI) in humans. | 03-31-2016 |
| 20160114000 | CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS - Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity. | 04-28-2016 |
| 20160136124 | ADMINISTRATION OF A FOOD COMPOSITION PRODUCT - Method for orally administrating a subject a food composition product, referred to as “Preload Meal,” before administering a main meal to the subject. The food composition product includes nutrients that stimulate the release of incretins in the subject prior to administration of the main meal, increasing satiety, lowering total energy intake from both the food composition product and the main meal, and contributing to a biological control of a post prandial blood sugar level and a post prandial insulin level in the subject. | 05-19-2016 |
| 20170232063 | USES OF CASEIN COMPOSITIONS | 08-17-2017 |
| 20180021251 | STIMULATION OF APPETITE AND TREATMENT OF ANOREXIA IN DOGS AND CATS | 01-25-2018 |
